Describing the Profile of Patients on Concurrent Rifampin and Warfarin Therapy in Western Kenya: A Case Series

• DOI: 10.1007/s40268-013-0023-7
• Publication Date: 2013-08-27T08:57:37Z
• Authors: M. W. Maina; S. D. Pastakia; I. Manji; N. Kirui; C. Kirwa; Rakhi Karwa
• Keywords: Pharmacotherapy; Therapeutic Drug Monitoring

Rifampicin's ability to induce hepatic enzymes is responsible for causing a clinically significant drug interaction with warfarin. Little data exists guide clinicians on managing this interaction, especially in Sub-Saharan Africa where many patients are exposed combination due higher burden of tuberculosis.The objective the case series provide insight practicing unique dynamics resource-constrained settings. The will details commonly encountered scenarios and dosage adjustments required maintain therapeutic INR.A retrospective chart review was conducted attending Moi Teaching Referral Hospital anticoagulation clinic Eldoret, Kenya. Patients were included if they had history concurrent rifampicin warfarin therapy minimum follow up 2 months. Descriptive statistics used explain demographic characteristics, time INR average weekly dose. inference proportions test compare range (TTR) rest not receiving clinic.Of 350 patient charts evaluated, 10 met inclusion criteria. median percentage increase dose from baseline 15.7%. For analysis, TTR 47%.Patients should be rigorously monitored regular checks adjustments. Empiric avoided but characteristics can aid understanding alterations seen INR.